THE WIRE · № 75547
Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study
01 THE MACHINE READ
WHY IT MATTERS.
First patient treated in an asthma neuromodulation feasibility study is early-stage device news with no named public issuer.
Very early device trial, no ticker named
Feasibility study results and IDE progress
Single-patient data, private company
FULL DISPATCH
IRVINE, Calif., Oct. 12, 2026 /PRNewswire/ -- Spiro Medical, Inc., a clinical-stage medical device company pioneering neuromodulation-based therapies for chronic respiratory diseases, today announced that it has treated its first patient suffering from severe, uncontrolled asthma as part...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
New drug shows multiple improvements for people with Parkinson's disease2026-10-12 10:21 UTC
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer2026-10-12 10:50 UTC
POPE LEO TO UNDERGO LUNG SURGERY THIS WEEK Pope Leo, 71, says doctors discovered a small growth on his lung during a routine health check. The pontiff said the growth was detected early and is well-contained, with surgery scheduled in the coming days. The Vatican expects recov2026-10-11 10:54 UTC
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease2026-10-11 17:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.